The Steering Committee has carefully reviewed published evidence on the management of dyslipidaemia, including its diagnosis, treatment, and prevention, as well as critical evaluation of diagnostic and therapeutic procedures, including benefit-risk assessment and cost-effectiveness indicators
Manufacturers are still working to increase production to meet the demand
Abstract Maintaining research and development (R&D) productivity at a sustainable level is one of the main challenges currently facing the pharmaceutical industry
SGLT2i prescriptions showed high model reliability (63.7%83.1%) and were consistently associated with key markers of cardiorenal vulnerability, such as reduced eGFR, intermediate HbA1c levels (5.5%8.1%), history of atherosclerotic cardiovascular disease, and heart failure
Diabetes Care 2009;32:13271334 [DOI] [PMC free article] [PubMed] [Google Scholar] 33